Amgen Kicks Off Week of Big Biotech Earnings

Source: Minyanville, Brett Chase (4/24/12)

"It's imperative that each company meets sales and profit targets for the past quarter, but investors are particularly interested in updates on drugs being developed as they represent future growth."

Minyanville, Brett Chase

When Amgen, the biggest of the big biotech companies, reports first-quarter earnings at the end of the day Tuesday, the focus will be on declining sales of key products, competitive threats, and plans for a mountain of cash.

Amgen is the first of the four biggest U.S. biotech companies to report quarterly earnings. Celgene releases earnings before markets open on Thursday and Gilead Sciences will report its results after markets close the same day. Biogen Idec reports Tuesday, May 1 before markets open.

It's imperative that each company meets sales and profit targets for the past quarter, but investors are particularly interested in updates on drugs being developed as they represent future growth. At least that's the case in three of the four storylines.

For Amgen, it's a tale of an aging giant that is the least nimble of the four. CEO Kevin Sharer will preside over his last quarterly conference call with investors as he prepares to step down and make way for new chief exec Robert Bradway next month. . .View Full Article

Biopharma Firm Assembles Elite AI Cancer Team
Source: Streetwise Reports (07/11/2025)

Rakovina Therapeutics Inc. (RKV:TSX.V) strengthens its AI-driven cancer program with a world-class advisory board and breakthrough drug discovery platforms. Read more about how Rakovina's expert-backed strategy and proprietary platforms support next-gen oncology drug development and potential licensing deals.

Canadian Biotech Targets Massive Cell Technology Gains
Source: Dr. Douglas Loe (07/10/2025)

Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently announced a partnership with Eledon Pharmaceuticals Inc. (ELDN:NASDAQ) to explore the utility of Eledon's clinical-stage anti-CD40L monoclonal antibody tegoprubart/AT-1501 for conferring sustainable immune evasion of pancreatic islets deployed into Sernova's Cell Pouch device. Read on to see why one Leede Financial Inc. analyst rates this stock as a Speculative Buy.

Vaccine Co. Secures European Regulatory Breakthrough Potential
Source: Dr. Jonathan Aschoff (07/07/2025)

GeoVax Labs Inc. (GOVX:NASDAQ) recently raised US$6 million, projected to find operations through the last quarter of 2025, according to a ROTH Capital Markets research note. The company also received highly favorable guidance for GEO-MVA, its prophylactic vaccine for Mpox and smallpox from The European Medicines Agency.

Biotech Co. Still a Buy Despite Manufacturing Setbacks
Source: Emily Bodnar (07/07/2025)

While it received a lower price target due to manufacturing setbacks, Jasper Therapeutics Inc. (JSPR:NASDAQ) is still a Buy, according to an H.C. Wainwright & Co. research note.

Biotech Firm Adjusts Placement Terms to Fuel U.S. Expansion
Source: Streetwise Reports (07/07/2025)

Canadian healthcare and clinical stage drug development company Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) updates the pricing and warrant terms for its previously announced non-brokered private placement. Read why one technical analyst thinks the stock is ready to break out.